Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111335 | 0.79 | IDH1 (0.40) | IDH1KDM4EMAP4K1ALDH1A1TNKS | |
| SCHEMBL411695 | 0.78 | AKR1C3 (0.46) | IDH1MAP4K1MTORALDH1A1BCL2 | |
| SCHEMBL23580661 | 0.71 | IDH1 (0.44) | IDH1MAP4K1MTORCYP11B2PIK3CA | |
| SCHEMBL12070761 | 0.71 | IDH1 (0.39) | IDH1MAP4K1MTORALDH1A1CCNC | |
| SCHEMBL9954716 | 0.71 | CYP11B2 (0.45) | IDH1MTORBCL2BECN1CCNC | |
| SCHEMBL1455890 | 0.70 | BCL2 (0.48) | MTORALDH1A1BCL2BECN1TNKS | |
| SCHEMBL30444356 | 0.70 | IDH1 (0.42) | IDH1MAP4K1TNKS | |
| SCHEMBL20574851 | 0.70 | IDH1 (0.42) | IDH1MAP4K1TNKS | |
| SCHEMBL17624112 | 0.69 | MAP4K1 (0.36) | IDH1KDM4EMAP4K1ALDH1A1CCNC | |
| SCHEMBL9988948 | 0.69 | CYP1A2 (0.44) | KDM4EALDH1A1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | IDH1 670/4885KDM4E 2731/4885MAP4K1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.